Tongjitang prices US IPO 33% below initial price range

The Chinese medicine maker becomes the first Mainland company to cut the size of a US offering this year as the fall-out from the equity market correction broadens.

The situation for Chinese companies seeking US listings became even more troublesome at the end of last week, when Tongjitang Chinese Medicines was forced to price its initial public offering at $10, 33% below the bottom of the original price range.

US-listed Mainland companies have been hit hard by the volatility and uncertainty that have followed in the wake of the stock market corrections over the past couple of weeks รป which was first triggered by a sharp sell-off...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: ipo | nyse | pharmaceuticals | merrill lynch | ubs

Print Edition

FinanceAsia Print Edition